HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer
Metrics: PDF 1653 views | HTML 2609 views | ?
Zhixiong Dong1,2,*, Yang Yang1,4,*, Shuxia Liu3, Jun Lu1, Baiqu Huang1 and Yu Zhang1
1Institute of Genetics and Cytology, The Key Laboratory of Molecular Epigenetic of Ministry of Education (MOE), Northeast Normal University, Changchun 130024, China
2Tianjin Key Laboratory of Animal and Plant Resistance, College of Life Sciences, Tianjin Normal University, Tianjin 300387, China
3The Key Laboratory of Polyoxometalates Science of Ministry of Education (MOE), College of Chemistry, Northeast Normal University, Changchun 130024, China
4Department of Biochemistry and Molecular Biology, Beijing Normal University, Beijing Key Laboratory, Beijing 100875, China
*These authors contributed equally to this work
Yu Zhang, email: [email protected]
Keywords: PAC-320; HDAC inhibitor; prostate tumor; apoptosis
Received: August 08, 2017 Accepted: November 14, 2017 Published: December 08, 2017
HDAC inhibitors (HDACis) have been demonstrated with profound antiproliferative activities in various tumor types. Previously, we screened several polyoxometalate HDACis based on our p21 luciferase promoter system and demonstrated that such HDACis have antitumor activity. Here, we further investigate the antitumor mechanism of PAC-320, a compound among the polyoxometalates, in human prostate cancer. We demonstrate that PAC-320 is a broad-spectrum HDACi and could inhibit growth of prostate cancer cells in vitro and in vivo. Furthermore, we find that PAC-320 induces cell cycle arrest at G2/M phase and apoptosis. Mechanically, PAC-320 induced cell cycle arrest is associated with an increase of p21 and decrease of cyclin A and cyclin B1, while PAC-320 induced apoptosis is mediated through mitochondria apoptotic pathway and is closely associated with increase of BH3-only proteins Noxa and Hrk. Meanwhile, we demonstrate that p38 MAPK pathway is involved in PAC-320 induced antiproliferative activities in prostate cancer. Taken together, our data indicates that PAC-320 has potent prostate cancer inhibitory activity in vitro and in vivo, which is mediated by G2/M cell cycle arrest and apoptosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.